BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9536213)

  • 1. Current concepts of polycystic ovary syndrome.
    Rosenfield RL
    Baillieres Clin Obstet Gynaecol; 1997 Jun; 11(2):307-33. PubMed ID: 9536213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL; Ehrmann DA
    Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovary syndrome.
    Azziz R; Carmina E; Chen Z; Dunaif A; Laven JS; Legro RS; Lizneva D; Natterson-Horowtiz B; Teede HJ; Yildiz BO
    Nat Rev Dis Primers; 2016 Aug; 2():16057. PubMed ID: 27510637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome and acne.
    Chuan SS; Chang RJ
    Skin Therapy Lett; 2010; 15(10):1-4. PubMed ID: 21076799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
    Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
    JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.
    Barnes RB
    J Endocrinol Invest; 1998 Oct; 21(9):567-79. PubMed ID: 9856411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic ovary syndrome.
    Goudas VT; Dumesic DA
    Endocrinol Metab Clin North Am; 1997 Dec; 26(4):893-912. PubMed ID: 9429864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
    Romualdi D; Guido M; Ciampelli M; Giuliani M; Leoni F; Perri C; Lanzone A
    Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary (Stein-Leventhal) syndrome: etiology, complications, and treatment.
    Hoyt KL; Schmidt MC
    Clin Lab Sci; 2004; 17(3):155-63. PubMed ID: 15314890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.
    Housman E; Reynolds RV
    J Am Acad Dermatol; 2014 Nov; 71(5):847.e1-847.e10; quiz 857-8. PubMed ID: 25437977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
    Toscano V; Bianchi P; Balducci R; Guglielmi R; Mangiantini A; Lubrano C; Sciarra F
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine control in polycystic ovary-like syndrome.
    Schoemaker J
    Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne.
    Timpatanapong P; Rojanasakul A
    J Dermatol; 1997 Apr; 24(4):223-9. PubMed ID: 9164062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome.
    Baskind NE; Balen AH
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():80-97. PubMed ID: 27137106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome: a dermatologic approach.
    Moura HH; Costa DL; Bagatin E; Sodré CT; Manela-Azulay M
    An Bras Dermatol; 2011; 86(1):111-9. PubMed ID: 21437531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is acne a sign of androgen excess disorder or not?
    Uysal G; Sahin Y; Unluhizarci K; Ferahbas A; Uludag SZ; Aygen E; Kelestimur F
    Eur J Obstet Gynecol Reprod Biol; 2017 Apr; 211():21-25. PubMed ID: 28178574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences.
    Falsetti L; Gambera A; Andrico S; Sartori E
    Gynecol Endocrinol; 2002 Aug; 16(4):275-84. PubMed ID: 12396556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.